A Maryland jury ordered a unit of
to pay $505 million to
in a case involving IGEN's blood-testing technology.
Roche has been contesting claims since 1997 that its Boehringer Mannheim unit breached agreements covering the technology. IGEN said the jury confirmed its rights to terminate the licensing agreement with Roche and confirmed IGEN's rights to Roche's Elecsys Systems diagnostics product line.
Roche plans to appeal the ruling. On Instinet, IGEN was gaining 23% to $46.99.